Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

Overview of attention for article published in The Lancet HIV, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 17 news outlets
blogs: 1 blog

twitter: 6 X users
patent: 1 patent

Readers on

mendeley: 181 Mendeley

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 14,028 followers.

New article: Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. https://t.co/P5pFA1JWRV

Priddy and colleagues study on AAV vectored immunotherapy published in The Lancet HIV here https://t.co/BiYi0KVWpa

Adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunization to induce sustained expression of neutralizing antibodies to prevent HIV. #UMKCRCT https://t.co/cvRVPWu1BK

.@TheLancetHIV : Adeno-associated virus vectored immunoprophylaxis to prevent #HIV in healthy adults: a phase 1 randomised controlled trial https://t.co/2bdrjfhcUK https://t.co/R60s58ZZs8

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.